Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

Meet the Author: prof. dr. Mark Levis

In this e-learning, author prof. dr. Mark Levis will be queried about the ADMIRAL trial by an expert panel of hematologists, led by prof. dr. Gerwin Huls. They will discuss the ADMIRAL trial in relapsed / refractory acute myeloid leukemia.

In this phase III trial, the FLT3-inhibitor gilteritinib was compared to salvage chemotherapy treatment of relapse or refractory acute myeloid leukemia with a mutation in the FLT3 gene.

This program provides the opportunity to gain thorough understanding of the ADMIRAL trial. Together with the key author, the expert panel will offer profound insight into how this study was setup and executed. In addition, they will discuss the results of the trial and assess how these could impact daily clinical practice.  

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML Perl AE, Martinelli G, Levis MJ, et al. N Engl J Med 2019; 381:1728-1740


  • prof. Mark Levis, MD - hematologist, Johns Hopkins Medicine, Baltimore, USA


  • prof. Gerwin Huls, MD - hematologist, UMCG, Groningen, The Netherlands;
  • prof. Marc Raaijmakers, MD - hematologis, Erasmus MC, Rotterdam, The Netherlands;
  • Saskia Klein, MD, PhD - hematologist, MeanderMC, Amersfoort, The Netherlands
  • Sponsors

    This program is editorially independent and is financially supported by:

Related items